EVENT / PUBLIC SOURCE RECORD
Trade mission: Advancing Norwegian radiopharma and precision oncology in Japan
- The ended trade mission ran June 23–27, 2025, in Tokyo and Osaka. Innovation Norway organised it to introduce Norwegian radiopharma and precision-oncology expertise to Japan. The page says the mission showcased imaging, diagnostics, and cancer-treatment organisations and was intended to build collaboration with Japanese partners.
- The staged agenda: June 23 in Tokyo, regulatory briefings, roundtables, and preparation sessions; June 24, parallel tracks with meetings with Japanese pharmaceutical authorities and institution visits, alongside a Nordic introduction to Japan’s health system, regulation, and market; June 25–26 in Osaka, Nordic Health Expo Japan at EXPO 2025, site visits, and sessions on innovation, data, and diagnostics; June 27 in Tokyo, Nordic Health Summit Japan with investor/partnering activities, curated matchmaking, and strategic discussions. The page says the programme was fixed and focused on Norwegian contributions to advanced cancer diagnostics and treatment.
- Participating organisations shown: Agilera Pharma, Bayer Norway, GE Healthcare, NorTrials, Norwegian Cancer Society, Norsk Medisinsk Syklotronsenter, Oslo Cancer Cluster, Oslo University Hospital, and LMI.
- Contacts listed include Michal Louis Berg (Senior Market Advisor / Investment Manager, Tokyo; michal.louis.berg@innovationnorway.no), Marianne Støren Berg (Counsellor Science, Technology and Higher Education, Japan; marianne.storen.berg@innovationnnorway.no), Yuko Yasuda (Senior Market Advisor; yuko.yasuda@innovationnorway.no), Rasmus Malmborg (Investment Manager, health and life science, Oslo; rasmus.malmborg@innovasjonnorge.no), Tone Varslot Stave (Head of national export initiative on health and life science; tone.varslot.stave@innovasjonnorge.no), Jutta Heix (Head of International Affairs, Oslo Cancer Cluster; jh@oslocancercluster.no), and Monica Larsen (Senior Advisor, LMI; monica@lmi.no).
- The page links related content on Norwegian theranostics and biopharma and a GE Healthcare solution. Its participation conditions require ESG-aligned responsible business, adherence to the UN Guiding Principles and OECD Guidelines, and company due diligence to prevent or mitigate adverse impacts.